SLC5A2 and type 2 diabetes mellitus: Recent major clinical trials of commercially available SGLT2-selective inhibitors have proven to substantially lower cardiovascular events in patients affected with type 2 diabetes mellitus (T2DM) [3, 4], or even had a dual beneficial effect on major cardiovascular and renal events (MARCE) in T2DM as reported by the CANVAS investigators [5].